Summary
48 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: ¥5.29B against ¥29.1M.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 5.0% a year over the last 3 years.
- It earns only 1.8 CNY a year on every 100 CNY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 14.3 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue fell by 5.0% a year over 5 years. Over the last 3 years it fell by 5.0% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 CNY of revenue goes
- Cost of sales 65 CNY
- Research and development 6.1 CNY
- Sales and administration 25 CNY
- Taxes and other -5.3 CNY
- Net profit 8.5 CNY
Net profit, industry median (Medical - Healthcare Information Services) 4.7 CNY
Out of every 100 CNY of revenue, 8.5 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.